GRAIL (GRAL) is back in focus after unveiling detailed PATHFINDER 2 and NHS-Galleri data at ASCO 2026, highlighting early cancer detection gains and a low false positive rate when its Galleri test is used as a complement to standard screening.

Those ASCO results have arrived alongside a sharp move in the stock, with a 1-day share price return of 8.87% and a 30-day share price return of 22.33%. However, the year-to-date share price return is still down 25.12%, while the 1-year total shareholder return is 68.52%. This suggests momentum has recently picked up after a weaker patch earlier in the year.

If Galleri’s data has you looking across the broader cancer and diagnostics space, this is a good moment to scan other opportunities in healthcare AI using our stock screener. You can start with 40 healthcare AI stocks.

With GRAL almost in line with analyst targets and revenue still far from covering its losses, the question is whether recent trial data leaves upside on the table for new buyers or if the market is already pricing in future growth.

Most Popular Narrative: 48.8% Undervalued

The most followed narrative pegs GRAIL’s fair value at $130, almost double the last close of $66.55, framing the recent rally as only part of the story.

The NHS Galleri trial and PATHFINDER 2 together create a large body of randomized and registrational data on stage shift and safety, which can support broader physician adoption and, over time, help Galleri testing volumes and screening revenue.

Curious what kind of revenue ramp, margin lift and valuation multiple are baked into that fair value, and how long the story runs. The answers might surprise you.

Result: Fair Value of $130 (UNDERVALUED)

However, this bullish setup still leans heavily on regulatory and reimbursement decisions, while ongoing losses and any slowdown in test adoption could quickly challenge the upside story.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Another View: Rich On Sales Today

The bullish $130 fair value leans on long term earnings potential, but the current P/S of 18.3x already sits well above both the US Biotechs average of 10.7x and a fair ratio of 7x. This points to valuation risk if sentiment cools.

For context, that gap means you are paying a higher price for each dollar of current revenue than both the wider industry and what the fair ratio suggests the market could move towards over time. The real question is how much execution risk you are comfortable carrying at this entry point. See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Reading this, you can see there is a mix of enthusiasm and caution around GRAL. It makes sense to move quickly and test the story against the underlying data yourself. To see both sides laid out clearly, take a closer look at the 2 key rewards and 4 important warning signs.

Looking for more investment ideas?

If you stop with just one stock, you risk missing other opportunities that fit your style, so widen your search now and compare what else is out there.

• Target potential bargains by scanning companies that pass strict quality and value filters using the 46 high quality undervalued stocks.
• Prioritize resilience by checking out the 65 resilient stocks with low risk scores and see which stocks score well on stability and risk controls.
• Spot promising stories before the crowd notices by reviewing the screener containing 22 high quality undiscovered gems and see which lesser known businesses stand out on fundamentals.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.